Skip to main content
. 2015 Aug 17;6(31):31030–31038. doi: 10.18632/oncotarget.5208

Figure 3. In vitro validation of the involvement of TFEB1 in drug resistance.

Figure 3

A. HeyA8-MDR cells were treated with TFEB1 siRNA. Apoptosis was monitored using increasing doses of paclitaxel. Drug-sensitive HeyA8 cells and control siRNA-treated HeyA8-MDR cells were used as controls. B. Proportion of apoptotic cells was confirmed using PI staining by comparing with the control cells. C. A2780-CP cells were treated with TFEB1 siRNA. Drug-sensitive A2780 cells and control siRNA-treated A2780-CP cells were used as controls. D. Proportion of apoptotic cells after paclitaxel treatment was validated using PI staining as described above. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001.